Plasma Protein Therapeutics Market

Plasma Protein Therapeutics Market (Product - Coagulation Factors, Immunoglobulins, Albumins, C1-esterase Inhibitors, and Alpha-1 Proteinase Inhibitors and Hyperimmune Globulins; Application - Hemophilia, Primary Immunodeficiency Disorder, Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency (CLL, Multiple Myeloma, and Congenital AIDS), and Hereditary Angioedema, Kawasaki Disease, GBS, and CIDP) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2024

  • Rep Id : TMRGL10424
  • Published On : May 2018
  • No. of Pages : 144
  • Category : Pharmaceutical

Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology

Chapter 2 Executive Summary
2.1 Global Plasma Protein Therapeutics Market Snapshot

Chapter 3 Global Plasma Protein Therapeutics Market Revenue Analysis, 2014–2024 (US$ Mn) 
3.1 Introduction
3.2 Regulatory Scenario
3.3 Market Dynamics
     3.3.1 Drivers
     3.3.2 Restraints
     3.3.3 Opportunity
3.4 Market Attractiveness Analysis, by Region, 2015
3.5 Porter’s Five Forces Analysis
3.6 Global Plasma Protein Therapeutics Market Revenue Analysis, By Product Type, 2014–2024 (US$ Mn)
     3.6.1 Global Immunoglobulins Market Revenue, 2014–2024 (US$ Mn)
     3.6.2 Global Albumin Market Revenue, 2014–2024 (US$ Mn)
     3.6.3 Global Coagulation Factors Market Revenue, 2014–2024 (US$ Mn)
     3.6.4 Global C1-esterase Inhibitors Market Revenue, 2014–2024 (US$ Mn)
     3.6.5 Others (e.g. Alpha-1 Proteinase Inhibitors, Hyperimmune Globulins)
3.7 Global Plasma Protein Therapeutics Market Analysis, By Application, 2014–2024 (US$ Mn)
     3.7.1 Global Hemophilia Market Revenue, 2014–2024 (US$ Mn)
     3.7.2 Global Primary Immunodeficiency Disorder (PID) Market Revenue, 2014–2024 (US$ Mn)
     3.7.3 Global Idiopathic Thrombocytopenic Purpura (ITP) Market Revenue, 2014–2024 (US$ Mn)
     3.7.4 Global Secondary Immunodeficiency (e.g. CLL, Multiple Myeloma, Congenital AIDS, etc.) Market Revenue, 2014–2024 (US$ Mn)
     3.7.5 Others (e.g. Hereditary Angioedema, Kawasaki Disease, GBS, and CIDP, etc.)
3.8 Competitive Landscape
     3.8.1 Market Positioning of Key Players, 2015
     3.8.2 Recommendations
3.9 Pipeline Analysis
     3.9.1 Phase 1 and Phase 2 Drugs (Qualitative Analyses)
     3.9.2 Phase 3 and Phase 4 Drugs (Quantitative), Forecasts till 2024

Chapter 4 North America Plasma Protein Therapeutics Market Revenue Analysis, 2014–2024 (US$ Mn)
4.1 North America Plasma Protein Therapeutics Market Revenue, By Product Type, 2014–2024 (US$ Mn)
     4.1.1 North America Immunoglobulins Market Revenue, 2014–2024 (US$ Mn)
     4.1.2 North America Albumin Market Revenue, 2014–2024 (US$ Mn)
     4.1.3 North America Coagulation Factors Market Revenue, 2014–2024 (US$ Mn)
     4.1.4 North America C1-esterase Inhibitors Market Revenue, 2014–2024 (US$ Mn)
     4.1.5 Others
4.2 North America Plasma Protein Therapeutics Market Revenue, By Application, 2014–2024 (US$ Mn)
     4.2.1 North America Hemophilia Market Revenue, 2014–2024 (US$ Mn)
     4.2.2 North America Primary Immunodeficiency Disorder (PID) Market Revenue, 2014–2024 (US$ Mn)
     4.2.3 North America Idiopathic Thrombocytopenic Purpura (ITP) Market Revenue, 2014–2024 (US$ Mn)
     4.2.4 North America Secondary Immunodeficiency (e.g. CLL, Multiple Myeloma, and Congenital AIDS, etc.) Market Revenue, 2014–2024 (US$ Mn)
     4.2.5 Others (e.g. Hereditary Angioedema, Kawasaki Disease, GBS, and CIDP, etc.)
4.3 North America Plasma Protein Therapeutics Market Revenue, by Country 2014–2024 (US$ Mn)

Chapter 5 Europe Plasma Protein Therapeutics Market Revenue, 2014–2024 US$ Mn)
5.1 Europe Plasma Protein Therapeutics Market Revenue, By Product Type, 2014–2024 (US$ Mn)
     5.1.1 Europe Immunoglobulins Market Revenue, 2014–2024 (US$ Mn)
     5.1.2 Europe Albumin Market Revenue, 2014–2024 (US$ Mn)
     5.1.3 Europe Coagulation Factors Market Revenue, 2014–2024 (US$ Mn)
     5.1.4 Europe C1-esterase Inhibitors Market Revenue, 2014–2024 (US$ Mn)
     5.1.5 Others
5.2 Europe Plasma Protein Therapeutics Market Revenue, By Application, 2014–2024 (US$ Mn)
     5.2.1 Europe Hemophilia Market Revenue, 2014–2024 (US$ Mn)
     5.2.2 Europe Primary Immunodeficiency Disorder (PID) Market Revenue, 2014–2024 (US$ Mn)
     5.2.3 Europe Idiopathic Thrombocytopenic Purpura (ITP) Market Revenue, 2014–2024 (US$ Mn)
     5.2.4 Europe Secondary Immunodeficiency (e.g. CLL, Multiple Myeloma, Congenital AIDS, etc.) Market Revenue, 2014–2024 (US$ Mn)
     5.2.5 Others (e.g. Hereditary Angioedema, Kawasaki Disease, GBS, and CIDP, etc.)
     5.3 Europe Plasma Protein Therapeutics Market Revenue, by Country, 2014–2024 (US$ Mn) 

Chapter 6 Asia Pacific Plasma Protein Therapeutics Market Revenue Analysis, 2014–2024 (US$ Mn)
6.1 Asia Pacific Plasma Protein Therapeutics Market Revenue, By Product Type, 2014–2024 (US$ Mn)
     6.1.1 Asia Pacific Immunoglobulins Market Revenue, 2014–2024 (US$ Mn)
     6.1.2 Asia Pacific Albumin Market Revenue, 2014–2024 (US$ Mn)
     6.1.3 Asia Pacific Coagulation Factors Market Revenue, 2014–2024 (US$ Mn)
     6.1.4 Asia Pacific C1-esterase inhibitors Market Revenue, 2014–2024 (US$ Mn)
     6.1.5 Others
6.2 Asia Pacific Plasma Protein Therapeutics Market Revenue, By Application, 2014–2024 (US$ Mn)
     6.2.1 Asia Pacific Hemophilia Market Revenue, 2014–2024 (US$ Mn)
     6.2.2 Asia Pacific Primary Immunodeficiency Disorder (PID) Market Revenue, 2014–2024 (US$ Mn)
     6.2.3 Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Market Revenue, 2014–2024 (US$ Mn)
     6.2.4 Asia Pacific Secondary Immunodeficiency (e.g. CLL, Multiple Myeloma, and Congenital AIDS, etc.) Market Revenue, 2014–2024 (US$ Mn)
     6.2.5 Others (e.g. Hereditary Angioedema, Kawasaki Disease, GBS, and CIDP, etc.)
6.3 Asia Pacific Plasma Protein Therapeutics Market by Geography, Market Revenue, 2014–2024 (US$ Mn) 

Chapter 7 Latin America Plasma Protein Therapeutics Revenue Analysis, 2014–2024 (US$ Mn)
7.1 Latin America Plasma Protein Therapeutics Market Revenue Analysis, By Product Type, 2014–2024 (US$ Mn)
     7.1.1 Latin America Immunoglobulins Market Revenue, 2014–2024 (US$ Mn)
     7.1.2 Latin America Albumin Market Revenue, 2014–2024 (US$ Mn)
     7.1.3 Latin America Coagulation Factors Market Revenue, 2014–2024 (US$ Mn)
     7.1.4 Latin America C1-esterase Inhibitors Market Revenue, 2014–2024 (US$ Mn)
     7.1.5 Others
7.2 Latin America Plasma Protein Therapeutics Market Revenue, By Application, 2014–2024 (US$ Mn)
     7.2.1 Latin America Hemophilia Market Revenue, 2014–2024 (US$ Mn)
     7.2.2 Latin America Primary Immunodeficiency Disorder (PID) Market Revenue, 2014–2024 (US$ Mn)
     7.2.3 Latin America Idiopathic Thrombocytopenic Purpura (ITP) Market Revenue, 2014–2024 (US$ Mn)
     7.2.4 Latin America Secondary Immunodeficiency (e.g. CLL, Multiple Myeloma, and Congenital AIDS, etc.) Market Revenue, 2014–2024 (US$ Mn)
     7.2.5 Others (e.g. Hereditary Angioedema, Kawasaki Disease, GBS, and CIDP, etc.)
7.3 Latin America Plasma Protein Therapeutics Market by Geography, Market Revenue, 2014–2024 (US$ Mn) 

Chapter 8 Rest of the World (RoW) Plasma Protein Therapeutics Market Revenue Analysis, 2014–2024 (US$ Mn)
8.1 Rest of World Plasma Protein Therapeutics Market Revenue Analysis, By Product Type, 2014–2024 (US$ Mn)
8.2 Rest of World Plasma Protein Therapeutics Market Revenue, By Application, 2014–2024 (US$ Mn) 

Chapter 9 Company Profiles
9.1 Baxter International
     9.1.1 Company Overview
     9.1.2 Product Portfolio
     9.1.3 Financial Overview
     9.1.4 Business Strategies
     9.1.5 Recent Development
9.2 Biotest 
     9.2.1 Company Overview
     9.2.2 Product Portfolio
     9.2.3 Financial Overview
     9.2.4 Recent Development
9.3 CSL Behring
     9.3.1 Company Overview
     9.3.2 Product Portfolio
     9.3.3 Financial Overview
     9.3.4 Business Strategies
     9.3.5 Recent Development
9.4 China Biologics
     9.4.1 Company Overview
     9.4.2 Product Portfolio
     9.4.3 Financial Overview
     9.4.4 Business Strategies
     9.4.5 Recent Development
9.5 GRIFOLS, S.A.
     9.5.1 Company Overview
     9.5.2 Product Portfolio
     9.5.3 Financial Overview
     9.5.4 Business Strategies
     9.5.5 Recent Development
9.6 Kedrion
     9.6.1 Company Overview
     9.6.2 Product Portfolio
     9.6.3 Financial Overview
     9.6.4 Recent Development
9.7 Octapharma USA, Inc.
     9.7.1 Company Overview
     9.7.2 Product Portfolio
     9.7.3 Financial Overview
     9.7.4 Recent Development
9.8 Shire Plc.
     9.8.1 Company Overview
     9.8.2 Product Portfolio
     9.8.3 Financial Overview
     9.8.4 Business Strategies
     9.8.5 Recent Development

List of Tables

Table 1. Plasma Protein Therapeutics Market Snapshot
Table 2. Global Plasma Protein Therapeutics Market Revenue, by Product Type, (US$ Mn), 2014–2024
Table 3. Global Plasma Protein Therapeutics Market Revenue, by Application, (US$ Mn), 2014–2024
Table 4. Global Plasma Protein Therapeutics Market Revenue, by Region, (US$ Mn), 2014–2024
Table 5. Pipeline Analysis (Phase I and Phase II)
Table 6. Pipeline Analysis (Phase III): Plasma protein Therapeutics, Expected Launch date of Approval to 2024 (US$ Mn)
Table 7. North America Plasma Protein Therapeutics Market Revenue, by Product Type, (US$ Mn), 2014–2024
Table 8. North America Plasma Protein Therapeutics Market Revenue, by Application, (US$ Mn), 2014–2024
Table 9. North America Plasma Protein Therapeutics Market Revenue, by Countries, (US$ Mn), 2014–2024
Table 10. Europe Plasma Protein Therapeutics Market Revenue, by Product Type, (US$ Mn), 2014–2024
Table 11. Europe Plasma Protein Therapeutics Market Revenue, by Application, (US$ Mn), 2014–2024
Table 12. Europe Plasma Protein Therapeutics Market Revenue, by Countries, (US$ Mn), 2014–2024
Table 13. Asia Pacific Plasma Protein Therapeutics Market Revenue, by Product Type, (US$ Mn), 2014–2024
Table 14. Asia Pacific Plasma Protein Therapeutics Market Revenue, by Application, (US$ Mn), 2014–2024
Table 15. Asia Pacific Plasma Protein Therapeutics Market Revenue by Countries, (US$ Mn), 2014–2024
Table 16. LATAM Plasma Protein Therapeutics Market Revenue, by Product Type, (US$ Mn), 2014–2024
Table 17. LATAM Plasma Protein Therapeutics Market Revenue, by Application, (US$ Mn), 2014–2024
Table 18. Latin America Plasma Protein Therapeutics Market Revenue, by Countries, (US$ Mn), 2014–2024
Table 19. ROW Plasma Protein Therapeutics Market Revenue, by Product Type, (US$ Mn), 2014–2024
Table 20. ROW Plasma Protein Therapeutics Market Revenue, by Application, (US$ Mn), 2014–2024

 

List of Figures

FIG. 1 Global Plasma Protein Therapeutics Market Revenue, (US$ Mn), 2014–2024.
FIG. 2 Global Plasma Protein Therapeutics Market Revenue, by Product Type (US$ Mn), 2014–2024
FIG. 3 Global Plasma Protein Therapeutics Market Revenue, by Application (US$ Mn), 2014–2024
FIG. 4 Global Plasma Protein Therapeutics Market, by Geography (%), 2015
FIG. 5 Global Plasma Protein Therapeutics Market, by Geography (%), 2024
FIG. 6 Market Attractiveness Analysis, by Geography (2015)
FIG. 7 Porter’s Five Forces Analysis
FIG. 8 Global Immunoglobulin Market Revenue, (US$ Mn), 2014–2024
FIG. 9 Global Albumin Market Revenue, (US$ Mn), 2014–2024
FIG. 10 Global Coagulation Factor Market Revenue, (US$ Mn), 2014–2024
FIG. 11 Global C1 Esterase Inhibitors Market Revenue, (US$ Mn), 2014–2024
FIG. 12 Other Plasma-derived Proteins Market Revenue, (US$ Mn), 2014–2024
FIG. 13 Global Hemophilia Market Revenue, (US$ Mn), 2014–2024
FIG. 14 Global Primary Immunodeficiency Disorder (PID) Market Revenue, (US$ Mn), 2014–2024
FIG. 15 Global Idiopathic Thrombocytopenic Purpura Market Revenue, (US$ Mn), 2014–2024
FIG. 16 Global Secondary Immunodeficiency Market Revenue, (US$ Mn), 2014–2024
FIG. 17 Global Hereditary Angioedema Market Revenue, (US$ Mn), 2014–2024
FIG. 18 Other Application Market Revenue, (US$ Mn), 2014–2024
FIG. 19 Market Positioning of Key Players, 2015
FIG. 20 North America Immunoglobulin Market Revenue, (US$ Mn), 2014–2024
FIG. 21 North America Albumin Market Revenue, (US$ Mn), 2014–2024
FIG. 22 North America Coagulation Factor Market Revenue, (US$ Mn), 2014–2024
FIG. 23 North America C1 Esterase Inhibitors Market Revenue, (US$ Mn), 2014–2024
FIG. 24 North America Primary Immunodeficiency Disorder (PID) Market Revenue, (US$ Mn), 2014–2024
FIG. 25 North America Idiopathic Thrombocytopenic Purpura Market Revenue, (US$ Mn), 2014–2024
FIG. 26 North America Secondary Immunodeficiency Market Revenue, (US$ Mn), 2014–2024 
FIG. 27 Europe Immunoglobulin Market Revenue, (US$ Mn), 2014–2024
FIG. 28 Europe Albumin Market Revenue, (US$ Mn), 2014–2024
FIG. 29 Europe Coagulation Factor Market Revenue, (US$ Mn), 2014–2024 
FIG. 28 Europe C1 Esterase Inhibitors Market Revenue, (US$ Mn), 2014–2024
FIG. 29 Europe Primary Immunodeficiency Disorder (PID) Market Revenue, (US$ Mn), 2014–2024
FIG. 30 Europe Idiopathic Thrombocytopenic Purpura Market Revenue, (US$ Mn), 2014–2024
FIG. 31 Europe Secondary Immunodeficiency Market Revenue, (US$ Mn), 2014–2024
FIG. 32 Asia Pacific Immunoglobulin Market Revenue, (US$ Mn), 2014–2024
FIG. 33 Asia Pacific Albumin Market Revenue, (US$ Mn), 2014–2024
FIG. 34 Asia Pacific Coagulation Factor Market Revenue, (US$ Mn), 2014–2024
FIG. 35 Asia Pacific C1 Esterase Inhibitors Market Revenue, (US$ Mn), 2014–2024
FIG. 36 Asia Pacific Primary Immunodeficiency Disorder (PID) Market Revenue, (US$ Mn), 2014–2024
FIG. 37 Asia Pacific Idiopathic Thrombocytopenic Purpura Market Revenue, (US$ Mn), 2014–2024
FIG. 38 Asia Pacific Secondary Immunodeficiency Market Revenue, (US$ Mn), 2014–2024
FIG. 39 LATAM Immunoglobulin Market Revenue, (US$ Mn), 2014–2024
FIG. 40 LATAM Albumin Market Revenue, (US$ Mn), 2014–2024
FIG. 41 LATAM Coagulation Factor Market Revenue, (US$ Mn), 2014–2024
FIG. 42 LATAM C1 Esterase inhibitors Market Revenue, (US$ Mn), 2014–2024
FIG. 43 LATAM Primary Immunodeficiency Disorder (PID) Market Revenue, (US$ Mn), 2014–2024
FIG. 44 LATAM Idiopathic Thrombocytopenic Purpura Market Revenue, (US$ Mn), 2014–2024
FIG. 45 LATAM Secondary Immunodeficiency Market Revenue, (US$ Mn), 2014–2024
FIG. 46 Baxter International Segmental Financial Overview: 2013–2015 (US$ Mn)
FIG. 47 Baxter International Geographical Financial Overview: 2013–2015 (US$ Mn)
FIG. 48 Biotest Financial Overview: 2013–2015 (US$ Mn)
FIG. 49 CSL Behring Segmental Financial Overview: 2013–2015 (US$ Mn)
FIG. 50 CSL Behring Geographical Financial Overview: 2013–2015 (US$ Mn)
FIG. 51 China Biologics Segmental Financial Overview: 2013–2015 (US$ Mn)
FIG. 52 GRIFOLS, S.A. Segmental Financial Overview: 2013–2015 (US$ Mn)
FIG. 53 GRIFOLS, S.A. Geographical Financial Overview: 2013–2015 (US$ Mn)
FIG. 54 Kedrion Financial Overview: 2012–2014 (US$ Mn)
FIG. 55 Octapharma USA, Inc. Financial Overview: 2012–2014 (US$ Mn)
FIG. 56 Shire Plc. Segmental Financial Overview: 2013–2015 (US$ Mn)
FIG. 57 Shire Plc. Geographical Financial Overview: 2013–2015 (US$ Mn)

.